-
Something wrong with this record ?
International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members
IJ. Beijert, L. Cheng, F. Liedberg, K. Plass, SR. Williamson, P. Gontero, MJ. Ribal, M. Babjuk, PC. Black, AM. Kamat, F. Algaba, DM. Berman, A. Hartmann, A. Masson-Lecomte, M. Rouprêt, A. Lopez-Beltran, H. Samaratunga, SF. Shariat, AH. Mostafid,...
Status not-indexed Language English Country Netherlands
Document type Journal Article
NLK
Directory of Open Access Journals
from 2020
PubMed Central
from 2020
ROAD: Directory of Open Access Scholarly Resources
from 2020
- Publication type
- Journal Article MeSH
BACKGROUND: Grade of non-muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1-3, and WHO2004 categories: papillary urothelial neoplasm of low malignant potential [PUNLMP], low-grade [LG], high-grade [HG] carcinoma) are used. OBJECTIVE: To ask the European Association of Urology (EAU) and International Society of Urological Pathology (ISUP) members regarding their current practice and preferences of grading systems. DESIGN SETTING AND PARTICIPANTS: A web-based, anonymous questionnaire with ten questions on grading of NMIBC was created. The members of EAU and ISUP were invited to complete an online survey by the end of 2021. Thirteen experts had previously answered the same questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The submitted answers from 214 ISUP members, 191 EAU members, and 13 experts were analyzed. RESULTS AND LIMITATIONS: Currently, 53% use only the WHO2004 system and 40% use both systems. According to most respondents, PUNLMP is a rare diagnosis with management similar to Ta-LG carcinoma. The majority (72%) would consider reverting back to WHO1973 if grading criteria were more detailed. Separate reporting of WHO1973-G3 within WHO2004-HG would influence clinical decisions for Ta and/or T1 tumors according the majority (55%). Most respondents preferred a two-tier (41%) or a three-tier (41%) grading system. The current WHO2004 grading system is supported by a minority (20%), whereas nearly half (48%) supported a hybrid three- or four-tier grading system composed of both WHO1973 and WHO2004. The survey results of the experts were comparable with ISUP and EAU respondents. CONCLUSIONS: Both the WHO1973 and the WHO2004 grading system are still widely used. Even though opinions on the future of bladder cancer grading were strongly divided, there was limited support for WHO1973 and WHO2004 in their current formats, while the hybrid (three-tier) grading system with LG, HG-G2, and HG-G3 as categories could be considered the most promising alternative. PATIENT SUMMARY: Grading of non-muscle-invasive bladder cancer (NMIBC) is a matter of ongoing debate and lacks international consensus. We surveyed urologists and pathologists of European Association of Urology and International Society of Urological Pathology on their preferences regarding NMIBC grading to generate a multidisciplinary dialogue. Both the "old" World Health Organization (WHO) 1973 and the "new" WHO2004 grading schemes are still used widely. However, continuation of both the WHO1973 and the WHO2004 system showed limited support, while a hybrid grading system composed of both the WHO1973 and the WHO2004 classification system may be considered a promising alternative.
Anatomic Pathology Champalimaud Clinical Center Lisbon Portugal
Department of Cellular Pathology University Hospital of Wales Cardiff UK
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto ON Canada
Department of Morphological Sciences University of Cordoba Medical School Cordoba Spain
Department of Pathology and Molecular Medicine Queen's University Kingston ON Canada
Department of Pathology Aquesta Uropathology and University of Queensland Brisbane Australia
Department of Pathology Cleveland Clinic Cleveland OH USA
Department of Pathology Fundació Puigvert Universitat Autónoma de Barcelona Barcelona Spain
Department of Pathology Medical University Vienna Vienna General Hospital Vienna Austria
Department of Surgical Pathology Aichi Medical University Hospital Nagakute Japan
Department of Translational Medicine Lund University Malmö Sweden
Department of Urologic Sciences University of British Columbia Vancouver BC Canada
Department of Urology Caritas St Josef Medical Center University of Regensburg Regensburg Germany
Department of Urology Fundacio Puigvert Universitat Autònoma de Barcelona Barcelona Spain
Department of Urology Hospital Clínic de Barcelona Universitat de Barcelona Barcelona Spain
Department of Urology Skåne University Hospital Malmö Sweden
Department of Urology The Stokes Centre for Urology Royal Surrey Hospital Guildford UK
Department of Urology Université de Paris APHP Saint Louis Hospital Paris France
Department of Urology University of Texas MD Anderson Cancer Center Houston TX USA
European Association of Urology Guidelines Office Board Arnhem The Netherlands
Institute of Pathology Friedrich Alexander University of Erlangen Nürnberg Erlangen Germany
Kingston Health Sciences Centre Queen's University Kingston ON Canada
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23009638
- 003
- CZ-PrNML
- 005
- 20230721095521.0
- 007
- ta
- 008
- 230707s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euros.2023.03.019 $2 doi
- 035 __
- $a (PubMed)37284047
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Beijert, Irene J $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands $u Department of Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands
- 245 10
- $a International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members / $c IJ. Beijert, L. Cheng, F. Liedberg, K. Plass, SR. Williamson, P. Gontero, MJ. Ribal, M. Babjuk, PC. Black, AM. Kamat, F. Algaba, DM. Berman, A. Hartmann, A. Masson-Lecomte, M. Rouprêt, A. Lopez-Beltran, H. Samaratunga, SF. Shariat, AH. Mostafid, M. Varma, S. Shen, M. Burger, T. Tsuzuki, J. Palou, EM. Compérat, RJ. Sylvester, TH. van der Kwast, BWG. van Rhijn, MR. Downes
- 520 9_
- $a BACKGROUND: Grade of non-muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1-3, and WHO2004 categories: papillary urothelial neoplasm of low malignant potential [PUNLMP], low-grade [LG], high-grade [HG] carcinoma) are used. OBJECTIVE: To ask the European Association of Urology (EAU) and International Society of Urological Pathology (ISUP) members regarding their current practice and preferences of grading systems. DESIGN SETTING AND PARTICIPANTS: A web-based, anonymous questionnaire with ten questions on grading of NMIBC was created. The members of EAU and ISUP were invited to complete an online survey by the end of 2021. Thirteen experts had previously answered the same questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The submitted answers from 214 ISUP members, 191 EAU members, and 13 experts were analyzed. RESULTS AND LIMITATIONS: Currently, 53% use only the WHO2004 system and 40% use both systems. According to most respondents, PUNLMP is a rare diagnosis with management similar to Ta-LG carcinoma. The majority (72%) would consider reverting back to WHO1973 if grading criteria were more detailed. Separate reporting of WHO1973-G3 within WHO2004-HG would influence clinical decisions for Ta and/or T1 tumors according the majority (55%). Most respondents preferred a two-tier (41%) or a three-tier (41%) grading system. The current WHO2004 grading system is supported by a minority (20%), whereas nearly half (48%) supported a hybrid three- or four-tier grading system composed of both WHO1973 and WHO2004. The survey results of the experts were comparable with ISUP and EAU respondents. CONCLUSIONS: Both the WHO1973 and the WHO2004 grading system are still widely used. Even though opinions on the future of bladder cancer grading were strongly divided, there was limited support for WHO1973 and WHO2004 in their current formats, while the hybrid (three-tier) grading system with LG, HG-G2, and HG-G3 as categories could be considered the most promising alternative. PATIENT SUMMARY: Grading of non-muscle-invasive bladder cancer (NMIBC) is a matter of ongoing debate and lacks international consensus. We surveyed urologists and pathologists of European Association of Urology and International Society of Urological Pathology on their preferences regarding NMIBC grading to generate a multidisciplinary dialogue. Both the "old" World Health Organization (WHO) 1973 and the "new" WHO2004 grading schemes are still used widely. However, continuation of both the WHO1973 and the WHO2004 system showed limited support, while a hybrid grading system composed of both the WHO1973 and the WHO2004 classification system may be considered a promising alternative.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Cheng, Liang $u Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Lifespan Academic Medical Center and Legorreta Cancer Center at Brown University, Providence, RI, USA
- 700 1_
- $a Liedberg, Fredrik $u Department of Translational Medicine, Lund University, Malmö, Sweden $u Department of Urology, Skåne University Hospital, Malmö, Sweden $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- 700 1_
- $a Plass, Karin $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands
- 700 1_
- $a Williamson, Sean R $u Department of Pathology, Cleveland Clinic, Cleveland, OH, USA
- 700 1_
- $a Gontero, Paolo $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Ribal, Maria J $u European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands $u Department of Urology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
- 700 1_
- $a Babjuk, Marko $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Black, Peter C $u Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
- 700 1_
- $a Kamat, Ashish M $u Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
- 700 1_
- $a Algaba, Ferran $u Department of Pathology, Fundació Puigvert, Universitat Autónoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Berman, David M $u Kingston Health Sciences Centre, Queen's University, Kingston, ON, Canada $u Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada
- 700 1_
- $a Hartmann, Arndt $u Institute of Pathology, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
- 700 1_
- $a Masson-Lecomte, Alexandra $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Université de Paris, APHP, Saint Louis Hospital, Paris, France
- 700 1_
- $a Rouprêt, Morgan $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Pitié Salpétrière Hospital, AP-HP, GRC n°5, ONCOTYPE-URO, Sorbonne University, Paris, France
- 700 1_
- $a Lopez-Beltran, Antonio $u Department of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain $u Anatomic Pathology, Champalimaud Clinical Center, Lisbon, Portugal
- 700 1_
- $a Samaratunga, Hemamali $u Department of Pathology, Aquesta Uropathology and University of Queensland, Brisbane, Australia
- 700 1_
- $a Shariat, Shahrokh F $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Mostafid, A Hugh $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK
- 700 1_
- $a Varma, Murali $u Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK
- 700 1_
- $a Shen, Steven $u Department of Pathology Genomic Medicine, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA
- 700 1_
- $a Burger, Maximilian $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Tsuzuki, Toyonori $u Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
- 700 1_
- $a Palou, Joan $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Compérat, Eva M $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Pathology, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Sylvester, Richard J $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands
- 700 1_
- $a van der Kwast, Theo H $u Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada
- 700 1_
- $a van Rhijn, Bas W G $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands $u European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Downes, Michelle R $u Division of Anatomic Pathology, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada $u Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- 773 0_
- $w MED00207999 $t European urology open science $x 2666-1683 $g Roč. 52, č. - (2023), s. 154-165
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37284047 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230721095514 $b ABA008
- 999 __
- $a ok $b bmc $g 1958443 $s 1195902
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 52 $c - $d 154-165 $e 20230510 $i 2666-1683 $m European urology open science $n Eur Urol Open Sci $x MED00207999
- LZP __
- $a Pubmed-20230707
